|
|
Article: Europe Approves Amgen's Pair: Aranesp, Neulasta In Oncology.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
As expected, the European Commission gave its marketing nod to Aranesp and Neulasta, the strong-selling U.S. oncology products from Amgen Inc.
The company's stock (NASDAQ:AMGN) closed Wednesday at $45.18, down 3 cents.
Amgen did not return repeated phone calls seeking comment, but Leah Rush Cann, senior vice president at Wachovia Corp. in New York, said in a research note that the approvals in Europe "could provide some potential upside to our numbers, but we think it will be important to observe how sales ramp in Europe."
Historically, Cann wrote, "drugs tend to ramp more slowly in countries outside of the U.S. due ...